(P043) Postoperative Bolus Electron Conformal Radiation Therapy for Soft Tissue Tumors: Initial Clinical Experience

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Bolus electron conformal radiation therapy for the postoperative treatment of superficial soft tissue tumors resulted in favorable tumor control outcomes and limited radiation-related toxicity.

Christen R. Elledge, Anupama Chundury, MD, Jessika Contreras, MD, Lindsey A. Olsen, PhD, James Kavanaugh, MS, Imran Zoberi, MD,  Jeffrey R. Olsen, MD; Georgetown University School of Medicine;    Washington University School of Medicine

BACKGROUND: Achieving a conformal dose distribution for treatment of superficial soft tissue tumors (SSTTs) often presents unique challenges for targets of variable depth adjacent to organs at risk. A machine-fabricated, patient-specific compensator for bolus electron conformal radiation therapy (BECRT) provides a potential solution to such anatomic challenges. The purpose of this study is to report the technique and clinical outcomes for patients with SSTTs treated with BECRT at a single institution.

METHODS: The records of seven patients with SSTTs treated with postoperative BECRT were reviewed under an institutional review board–approved protocol. Histologic subtypes included pleomorphic undifferentiated sarcoma (n = 2), angiosarcoma, clear cell sarcoma, leiomyosarcoma, synovial sarcoma, and dermatofibrosarcoma protuberans (DFSP). Disease sites included cheek, ear, foot, leg (n = 2), and posterior chest wall (n = 2). All patients underwent definitive resection (wide local excision), and one patient received concurrent paclitaxel for angiosarcoma histology. One patient received brachytherapy prior to BECRT. Patients were followed with routine clinical and magnetic resonance imaging examinations for local recurrence and CT imaging for metastatic disease (DFSP excluded). Acute and late toxicities were assessed using the Common Terminology Criteria for Adverse Events version 4.03.

RESULTS: Median follow-up time was 20.3 months. Median age was 71 years (range: 28–82 yr). All patients presented with localized disease, and margin status was close or positive in 3 of 7 patients. The median prescribed dose was 6,300 cGy (range: 5,000–6,300 cGy), with a median dose per fraction of 180 cGy (range: 180–200 cGy). At last follow-up, all patients were without local recurrence; one experienced distant progression 24 months after completion of BECRT. Acute grade 1 radiation dermatitis occurred in all patients, and acute grade 2 radiation dermatitis occurred in one patient; however there were no grade ≥ 3 acute or late toxicities.

CONCLUSIONS: BECRT for the postoperative treatment of SSTTs resulted in favorable tumor control outcomes and limited radiation-related toxicity.    

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content